Get the Stockscreener App
90.09
1.85%
-1.70
After Hours:
90.09
Edwards Lifesciences Corp stock is traded at $90.09, with a volume of 4.98M.
It is down -1.85% in the last 24 hours and up +5.85% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$91.79
Open:
$90.48
24h Volume:
4.98M
Relative Volume:
0.97
Market Cap:
$51.87B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
48.95
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
-4.99%
1M Performance:
+5.85%
6M Performance:
+8.41%
1Y Performance:
+15.09%
1-Day Range:
$88.20
$90.62
1-Week Range:
$88.20
$95.13
52-Week Range:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
90.09 | 52.85B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
88.96 | 160.44B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.07 | 127.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.30 | 106.97B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
42.63 | 66.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update - Moomoo
Edwards Lifesciences to pay record $10m for HSR evasion - Global Competition Review
Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance - MLex
RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating - marketscreener.com
Edwards Lifesciences stock reflects steady growth prospects in cardiovascular care - ad-hoc-news.de
Edwards Lifesciences stands out as US agency eyes broader access for heart valve device - MSN
Edwards Lifesciences CVP sells $56,762 in company stock - Investing.com UK
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Form 4 Edwards Lifesciences Corp For: 10 July By Investing.com - Investing.com India
Edwards Lifesciences CVP sells $56,762 in company stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CFO receives stock, performance unit and option grants - Stock Titan
Edwards Lifesciences (NYSE: EW) CVP exercises stock options and sells 619 shares - Stock Titan
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System - GlobeNewswire Inc.
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth - ad-hoc-news.de
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus - Kalkine Media
Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - ad-hoc-news.de
The Edwards SAPIEN 3 Ultra ValvePrecision Transcatheter Option For US Heart Patients - AD HOC NEWS
Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity - Investing.com Nigeria
Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com South Africa
Edwards Lifesciences (EW) executive has shares withheld for tax on vesting - Stock Titan
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp - ad-hoc-news.de
Edwards Lifesciences Investors Seek 1st OK For $39M Deal - Law360
EWEdwards Lifesciences Corp Latest SEC Filings - Finviz
EW Maintained by Evercore ISI Group -- Price Target Raised to $1 - GuruFocus
Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector - DirectorsTalk Interviews
Edwards Lifesciences stock leans on its core heart valve business - ad-hoc-news.de
Law firm investigates Edwards Lifesciences offi... - Pluang
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? - marketscreener.com
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com - Investing.com Nigeria
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick - Investing.com
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at 92.94 USD - Investing.com
What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - Yahoo Finance
Edwards Lifesciences highlights heart valve portfolio as investors watch long-term growth - AD HOC NEWS
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com Nigeria
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com - Investing.com Canada
TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock - Investing.com
Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan - Stock Titan
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences (EW) Gains FDA Approval for Ecliptis System - GuruFocus
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):